prednisone has been researched along with Contracture in 7 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Contracture: Prolonged shortening of the muscle or other soft tissue around a joint, preventing movement of the joint.
Excerpt | Relevance | Reference |
---|---|---|
"We investigated the effect of high-dose prednisone therapy in 33 boys with Duchenne muscular dystrophy." | 7.67 | Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. ( Brooke, MH; Fenichel, GM; Florence, JM; Griggs, RC; Kaiser, KK; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Signore, L, 1987) |
"We investigated the effect of high-dose prednisone therapy in 33 boys with Duchenne muscular dystrophy." | 3.67 | Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. ( Brooke, MH; Fenichel, GM; Florence, JM; Griggs, RC; Kaiser, KK; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Signore, L, 1987) |
"A 58-year-old white female who had regional enteritis for many years insidiously developed scleroderma." | 1.26 | Systemic sclerosis and regional enteritis occurring simultaneously. ( Shaps, RS; Stoopler, M, 1976) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (71.43) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bloom, JL | 1 |
Lin, C | 1 |
Imundo, L | 1 |
Guthery, S | 1 |
Stepenaskie, S | 1 |
Galambos, C | 1 |
Lowichik, A | 1 |
Bohnsack, JF | 1 |
Geffen, DB | 1 |
Horowitz, J | 1 |
Shaps, RS | 1 |
Stoopler, M | 1 |
Grisanti, MW | 1 |
Moore, TL | 1 |
Osborn, TG | 1 |
Haber, PL | 1 |
Brooke, MH | 1 |
Fenichel, GM | 1 |
Griggs, RC | 1 |
Mendell, JR | 1 |
Moxley, RT | 1 |
Miller, JP | 1 |
Kaiser, KK | 1 |
Florence, JM | 1 |
Pandya, S | 1 |
Signore, L | 1 |
Richier, JL | 1 |
Guérin, D | 1 |
Leblay, R | 1 |
Pony, JC | 1 |
Jamison, DL | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen[NCT01603407] | Phase 3 | 196 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Measures the total distance walked in 6 minutes averaged over all post-baseline follow-up visits through Month 36. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
Intervention | meters (Least Squares Mean) |
---|---|
Daily Prednisone | 384.95 |
Daily Deflazacort | 384.17 |
Intermittent Prednisone | 346.81 |
Forced vital capacity was measured during a spirometry test. Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
Intervention | liters (Least Squares Mean) |
---|---|
Daily Prednisone | 1.4 |
Daily Deflazacort | 1.4 |
Intermittent Prednisone | 1.5 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
Intervention | percentage of fractional shortening (Least Squares Mean) |
---|---|
Daily Prednisone | 33.74 |
Daily Deflazacort | 34.01 |
Intermittent Prednisone | 34.33 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
Intervention | bpm (Least Squares Mean) |
---|---|
Daily Prednisone | 94.10 |
Daily Deflazacort | 93.52 |
Intermittent Prednisone | 91.65 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
Intervention | percentage of ejection fraction (Least Squares Mean) |
---|---|
Daily Prednisone | 61.88 |
Daily Deflazacort | 62.65 |
Intermittent Prednisone | 62.45 |
"The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects.~The activities are graded as follows:~2 - Normal - no obvious modification of activity~1 - Modified method but achieves goal independent of physical assistance from another 0 - Unable to achieve independently This scale is ordinal with 34 as the maximum score indicating fully-independent function." (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
Intervention | score on a scale (Least Squares Mean) |
---|---|
Daily Prednisone | 23.7 |
Daily Deflazacort | 24.0 |
Intermittent Prednisone | 20.7 |
The number of participants who completed 36 months of follow-up on the originally assigned dosage (for weight) of study medication. (NCT01603407)
Timeframe: 3 years
Intervention | Participants (Count of Participants) |
---|---|
Daily Prednisone | 36 |
Daily Deflazacort | 36 |
Intermittent Prednisone | 37 |
(NCT01603407)
Timeframe: 36 months
Intervention | kilograms/square meter (Least Squares Mean) |
---|---|
Daily Prednisone | 18.9 |
Daily Deflazacort | 18.3 |
Intermittent Prednisone | 18.1 |
(NCT01603407)
Timeframe: 36 months
Intervention | centimeters (Least Squares Mean) |
---|---|
Daily Prednisone | 116.8 |
Daily Deflazacort | 115.3 |
Intermittent Prednisone | 119.9 |
(NCT01603407)
Timeframe: 36 months
Intervention | kilograms (Least Squares Mean) |
---|---|
Daily Prednisone | 26.3 |
Daily Deflazacort | 24.9 |
Intermittent Prednisone | 26.3 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
Intervention | milliseconds (Least Squares Mean) |
---|---|
Daily Prednisone | 115.59 |
Daily Deflazacort | 116.87 |
Intermittent Prednisone | 117.90 |
Quality of life was measured by parent/guardian self-report for all children utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life for the child. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits
Intervention | score on a scale (Least Squares Mean) |
---|---|
Daily Prednisone | 64.88 |
Daily Deflazacort | 63.71 |
Intermittent Prednisone | 61.33 |
Quality of life was measured by child self-report in children age 5 and older utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits
Intervention | score on a scale (Least Squares Mean) |
---|---|
Daily Prednisone | 67.39 |
Daily Deflazacort | 64.96 |
Intermittent Prednisone | 65.07 |
Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
Intervention | degrees (Mean) |
---|---|
Daily Prednisone | 4.39 |
Daily Deflazacort | 3.29 |
Intermittent Prednisone | 2.67 |
Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
Intervention | degrees (Mean) |
---|---|
Daily Prednisone | 4.05 |
Daily Deflazacort | 2.81 |
Intermittent Prednisone | 2.29 |
Reciprocal of time to rise from the floor (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
Intervention | rise/sec (Least Squares Mean) |
---|---|
Daily Prednisone | 0.24 |
Daily Deflazacort | 0.24 |
Intermittent Prednisone | 0.18 |
The TSQM Global Satisfaction with Treatment is a 14-item questionnaire that ranges from 0 - 100 with higher scores indicating better outcomes. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
Intervention | score on a scale (Least Squares Mean) |
---|---|
Daily Prednisone | 71.2 |
Daily Deflazacort | 67.8 |
Intermittent Prednisone | 65.1 |
1 review available for prednisone and Contracture
Article | Year |
---|---|
Eosinophilic fasciitis in children.
Topics: Child, Preschool; Contracture; Eosinophilia; Fasciitis; Humans; Joint Diseases; Male; Prednisone; Sk | 1989 |
6 other studies available for prednisone and Contracture
Article | Year |
---|---|
H syndrome: 5 new cases from the United States with novel features and responses to therapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Child; Child, Preschool; Contracture; Diagno | 2017 |
Gemcitabine-induced severe extremity edema with muscle contractures and subsequent prevention with prednisone.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Contracture; Deoxycytidine; Drug Interactions; Edem | 2000 |
Systemic sclerosis and regional enteritis occurring simultaneously.
Topics: Colostomy; Contracture; Crohn Disease; Female; Hand Deformities, Acquired; Humans; Middle Aged; Post | 1976 |
Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone.
Topics: Adolescent; Child; Child, Preschool; Contracture; Drug Evaluation; Electromyography; Humans; Male; M | 1987 |
[Therapeutic effect of alpha-tocopher- yl-quinone on muscular disorders of hyperthyroidism and of prolonged treatment by corticoids and antimitotics].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Asthenia; Busulfan; Chlorambucil; Cobal | 1969 |
Minor epileptic status with contractures.
Topics: Child; Contracture; Electroencephalography; Epilepsy; Female; Humans; Intelligence; Phenytoin; Predn | 1973 |